KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.

Krystal Biotech (NASDAQ:KRYS) has received a positive recommendation from the European Medicines Agency's Committee for ...

as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

If approved by the EC, the Company expects to market B-VEC under the registered European trademark, VYJUVEK. “Our team in Europe has been working tirelessly in preparation for Krystal’s first ...

Krystal Biotech reported $91.1 million in Q4 2024 VYJUVEK revenue vs. analysts’ revenue estimate of $91.35 million. Adjusted EPS was $1.58 per basic share vs. analysts’ EPS estimate of $1.85.

If approved by the EC, the Company expects to market B-VEC under the registered European trademark, VYJUVEK. “Our team in Europe has been working tirelessly in preparation for Krystal’s first ...